Next Article in Journal
Drug Delivery Strategies and Nanozyme Technologies to Overcome Limitations for Targeting Oxidative Stress in Osteoarthritis
Next Article in Special Issue
Exploring the Potent Anticancer Activity of Essential Oils and Their Bioactive Compounds: Mechanisms and Prospects for Future Cancer Therapy
Previous Article in Journal
Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer
Previous Article in Special Issue
Protective Potential of Saussurea costus (Falc.) Lipsch. Roots against Cyclophosphamide-Induced Pulmonary Injury in Rats and Its In Vitro Antiviral Effect
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Chemical Constituents and Their Biological Activities from Genus Styrax

1
Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No. 1200, Cailun Road, Shanghai 201203, China
2
School of Chemistry and Chemical Engineering, Henan Normal University, 46 East of Construction Road, Xinxiang 453007, China
3
Institute of Pharmacy, Pharmacy College of Henan University, Jinming District, Kaifeng 475004, China
4
Department of Biology, Philipps University, Karl-von-Frisch-Straße 8, 35043 Marburg, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceuticals 2023, 16(7), 1043; https://doi.org/10.3390/ph16071043
Submission received: 13 June 2023 / Revised: 14 July 2023 / Accepted: 19 July 2023 / Published: 22 July 2023

Abstract

:
Plants from the genus Styrax have been extensively used in folk medicines to treat diseases such as skin diseases and peptic ulcers and as an antiseptic and analgesic. Most Styrax species, especially Styrax tonkinensis, which is used as an expectorant, antiseptic, and analgesic in Chinese traditional medicine, could screen resin after external injury. Styrax is also used in folk medicines in Korea to treat sore throat, bronchitis, cough, expectoration, paralysis, laryngitis, and inflammation. Different parts of various Styrax species can be widely employed for ethnopharmacological applications. Moreover, for ethnopharmacological use, these parts of Styrax species can be applied in combination with other folk medicines. Styrax species consist of versatile natural compounds, with some of them exhibiting particularly excellent pharmacological activities, such as cytotoxic, acetylcholinesterase inhibitory, antioxidant, and antifungal activities. Altogether, these exciting results indicate that a comprehensive review of plants belonging to this genus is essential for helping researchers to continuously conduct an in-depth investigation. In this review, the traditional uses, phytochemistry, corresponding pharmacological activities, and structure–activity relationships of different Styrax species are clarified and critically discussed. More insights into potential opportunities for future research are carefully assessed.

1. Introduction

The genus Styrax has a widespread but dispersive distribution. It is found in East Asian, American, and Mediterranean regions. It is the largest genus of the Styracaceae family and contains approximately 130 species [1]. Styrax stands out from other genera in this family because it produces a resinous material known as benzoin resin. This resin is typically released when the bark is injured by sharp objects. It has been utilized in various regions across the globe for its aromatic properties, being commonly used in perfumes and cosmetics, and Styrax species have traditionally been used in herbal medicines for the treatment of various diseases [2]. Of note, many Styrax species, especially S. tonkinensis, which is used as an expectorant, antiseptic, and analgesic in Chinese traditional medicine, could screen resin after exterior injury [3,4]. As a folk medicine in Korea, S. japonica is used to treat cough, bronchitis, sore throat, inflammation, paralysis, laryngitis, and expectoration [5,6,7]. The resin from Styrax, mixed with other antibiotic substances and hardening material, is also indicated in Islamic medicine as working as a good dental restorative material [2]. The flower of S. japonicus sieb. et Zucc. is used in Chinese folk medicine to relieve pain such as sore throat pain and toothache [8]. The leaves and roots of Styrax suberifolium are typically used as traditional medicines in China to cure rheumatic diseases [9].
Furthermore, the extensive investigation of pharmacologically active compounds derived from various Styrax species has been ongoing for several decades. While numerous Styrax species have been studied, S. obassia and S. japonica have emerged as the most extensively researched species, encompassing studies ranging from phytochemistry to comprehensive pharmacological investigations (Figure 1). An example of the pharmacological potential of Styrax species was the inhibitory effect of benzofurans extracted from Styrax agrestis A. Chev. on acetylcholinesterase (AChE) in vitro [10]. Triterpenoids isolated from the resin of S. tonkinensis (Pier.) Craib showed promising antiproliferative and differentiation effects on human leukemia HL-60 cells [4]. Additionally, the hydroalcoholic extracts of S. camporum Pohl demonstrated effectiveness in reducing chromosome and DNA damage [11]. Another notable finding was the promotion of estrogen biosynthesis by egonol gentiobioside and egonol gentiotrioside from Styrax perkinsiae through the action of aromatase [12].
Despite significant progress in discovering natural compounds from Styrax species and elucidating their potential pharmacological activities, there is still a need for a comprehensive and focused discussion of this rapidly growing research area. With our continuous interests in natural products discovery and pharmacological research [13,14,15,16], our aim is to provide researchers with a convenient and comprehensive resource that offers detailed and concise profiles of the Styrax genus. This review encompasses the examination of structural diversity and the pharmacological and biological significance and presents the exciting future research prospects in this field.

2. Results and Discussion

2.1. Chemical Constituents

2.1.1. Lignans

Lignans are the major constituents isolated from Styrax species. Most lignans are benzofuran, tetrahydrofuran, and furofuran lignans, and they are found in the stem nucleus of S. perkinsiae, S. ferrugineus, S. macranthus, S. obassia, S. camporun, S. japonica, and S. officinalis L. [2]. S. perkinsiae contains 16 norlignans including 114 and lignans 15 and 16 [17,18]. Norlignans (2, 4, and 1719) from S. ferrugineus leaves were investigated and characterized [19]. Compounds 5 and 2035 were isolated from the stem bark of S. japonica by several research groups [7,20,21,22,23,24]. Meanwhile, lignans 4, 15, and 16 were also afforded from S. japonica seeds [25]. Constituents of S. obassia were investigated, and norlignans (2, 3, 6, and 36) were isolated [26]. Moreover, a series of reports revealed the presence of several benzofurans in S. obassia including 3742 [27,28,29,30,31]. Six benzofuran derivatives comprising 47, 14, and 4346 were afforded from the seeds of S. macranthus that grow in southwestern China [32,33]. Benzofurans 4, 15, 40, and 4749 were isolated from the hexane extract of the seeds of S. officinalis L. [34,35,36,37]. Thirteen compounds, 4, 15, 37, 3942, and 5055, were obtained from the ethyl acetate (EtOAc) extract of the fruits of S. agrestis [10]. Moreover, compounds 4, 17, and 56 were isolated from S. camporum, and their protective activities were continuously assessed in vivo [11,38]. Bertanha et al. isolated benzofuran nor-neolignan derivatives 4, 6, 17, 18, and 57 from the aerial parts of S. pohlii. Several lignans including 5865 were isolated from S. perkinsiae [39]. Seventeen phenylpropanoids were successfully isolated from the bark of S. suberifolius, including ten benzofuran derivatives (45, and 6673), two dihydrofuran derivatives (23 and 65), two new neolignans (74 and 75), and three benzalcohols (7678) [40]. Eight lignans (7985) were isolated from the leaves of S. tonkinensis (Pierre) Craib ex Hartw [41]. Two new phenylpropanoids (86 and 87) were isolated from the resin of S. tonkinensis (Pierre) Craib ex Hartw by Fang’s groups [42]. Two lignans (88 and 89) and five nor-lignan-type benzofurans, including 4 and 9093, were separated from S. argentifolius by Son’s group [43].

2.1.2. Terpenoids

Terpenoids were also obtained from the Styrax genus as one of its major constituents. It should be noted that a vast majority of the terpenoids isolated from the Styrax genus were pentacyclic triterpenoids. To date, these molecules were only found in four species of the Styrax genus. Compounds 94102 were isolated from the stem bark of S. japonica Sieb. et Zucc. by several research groups [20,22,44,45]. A phytochemical investigation on the fresh fruits of S. japonica Sieb. et Zucc. was also conducted, and four new triterpenoid glycosides including jegosaponins A–D (103106) were found [46]. Furthermore, S. japonica Sieb. et Zucc. continued to be investigated by Kwon’s group, and 107110 and taraxerol (94) were isolated [47]. In addition to the plants themselves, triterpenoids were also found from the resin of S. tonkinensis (Pier.) Craib containing 111119 [4,6]. A pentacyclic triterpenoid (120), three triterpenoid saponins styrax-saponins A-C (121123), and deacylsaponin (124) were also obtained from S. officinalis L. [48,49]. Moreover, several monoterpenes, such as α-terpineol, linalool, and geraniol, were isolated from the benzoe resin of S. officinalis L. [50]. Recently, two cinnamyl esters and seven pentacyclic triterpene acids (119, 125130) were separated and characterized from S. tonkinensis (Pierre) Craib ex Hartw [42,51]. A triterpenoid (131) was obtained from S. argentifolius very recently [43].

2.1.3. Aromatic Compounds

Aromatic compounds, as a small proportion, were reported in the Styrax genus as well. In the species of S. tonkinensis (Pier.) Craib, seven aromatic compounds including 132139 were reported [52,53]. Moreover, Kim and coworkers found 140 and 141 from the stem bark of S. japonica (SJ) [54]. In S. perkinsiae Rhed., 142 was separated [39]. Recently, a new epicatechin glucopyranoside, 143, and three mononuclear phenolic acid esters, 144146, were isolated from the bark of S. suberifolius Hook [40].

2.1.4. Steroids

Luo and coworkers reported that three steroids including stigmasterol (147), styraxosides A (148), and daucosterol (149) were obtained from the seeds of S. macranthus Perk [32]. Another Steroid named β-sitosterol (150) was reported in S. perkinsiae Rehder [17]. A sterol, 151, was separated from S. argentifolius H.L. Li by Son’s group [43].

2.1.5. Others

In addition to the commonly isolated products from the genus Styrax, other types of natural products were also reported with relatively limited numbers. For example, in 1973, a preliminary result regarding the seeds of S. officinalis L. showed that the oil content amounts to 50% [55]. Moreover, flavonoids are not frequently reported in the Styrax genus according to literature studies. Only four flavonoids including 152155 were isolated from the aerial parts of S. pohlii A. DC. and the leaves of S. camporum Pohl [56]. Later, two new polyketones, 156157, were isolated from Styrax camporum Pohl. [57]. Recently, two bioactive saponins, Jegosaponin A and B (158159), were extracted and subsequently identified from S. japonica Siebold et al. Zuccarini [58].

2.2. Chemical Constituents Biological Activities

2.2.1. Cytotoxic Activity

S. perkinsiae was investigated, and the cytotoxic activity of the compounds isolated from this species was tested through the colorimetric chemosensitivity assay with SRB. (Figure 2). Interestingly, 11 and 14 revealed cytotoxic activities in vitro against two breast cancer cell lines, MCF-7 (IC50 = 5.5 and 15.0 µg/mL, respectively) and MDA-MB-231 (IC50 = 3.81 and 13.71 µg/mL, respectively) [17].
Later, the cytotoxic activities of lignans isolated from S. camporum against three cell lines, namely, HeLa (human cervix carcinoma), C6 (rat glioma), and Hep-2 (larynx epidermoid carcinoma), were analyzed using the standard MTT. Compound 4 showed strong cytotoxic activities against the Hep-2 (IC50 = 3.6 µg/mL) and C6 (IC50 = 3.2 µg/mL) cell lines. Compound 17 exhibited significant cytotoxic activities against the HeLa (IC50 = 5.3 µg/mL) and C6 (IC50 = 4.9 µg/mL) cell lines. Compound 56 exhibited moderate cytotoxic activities against the Hep-2 (IC50 = 28.0 µg/mL), HeLa (IC50 = 31.7 µg/mL), and C6 (IC50 = 10.7 µg/mL) cell lines. Moreover, when combined, 4 and 17 exhibited higher cytotoxic activities than the hydroalcoholic extract or either of the lignans alone, with the lowest IC50 being 13.3 µg/mL [38,59].
Seven compounds isolated from S. obassia were screened for their cytotoxic activities against the HeLa, HL-60, and MCF-7 cell lines. Among them, compounds 3 and 5 exhibited significant antitumor properties. Compound 3 exhibited cytotoxicity against the HeLa (IC50 = 23.3 µg/mL), HL-60 (IC50 = 16.8 µg/mL), and MCF-7 cells (IC50 = 53.5 µg/mL). Meanwhile, compound 5 exhibited cytotoxicity against HeLa (IC50 = 23.3 µg/mL), HL-60 (IC50 = 47.8 µg/mL), and MCF-7 cells (IC50 = 27.9 µg/mL) [60].
Through the Cell Counting Kit-8 (CCK-8) test in vitro, compounds 86 and 87 were tested for their cytotoxic activities against five tumor cell lines (PC-3, MCF-7, A549, HeLa, and HepG-2). Among them, the cytotoxic effect of compound 86 was observed against the MCF-7 and HeLa cell lines (IC50 = 26.75 and 45.16 µM, respectively), which was better or similar to that of the positive control cisplatin (IC50 = 40.95 and 47.36 μM, respectively). Compound 86 exhibited moderate cytotoxicity against the PC-3 and HepG-2 cell lines. The other biomolecule, 87, displayed moderate cytotoxicity against MCF-7 cells (IC50 = 57.1 µM) [42].
Son’s group assessed the cytotoxicity and α-glucosidase inhibitory activity of isolated compounds from S. argentifolius. They suggested that the activities of triterpenoid 131 and norlignan-type benzofurans (4 and 9193) are superior to those of others including sterol 153 and lignans 88 and 89. The better activities of benzofurans (4 and 9193) were postulated to be an effect of the substitutions at the side chain of carbon C-5. Among them, compound 4 exhibited potential cytotoxicity against three cancer cell lines, namely, Lu (IC50 = 21.50 µg/mL), KB (IC50 = 22.11 µg/mL), and HepG-2 (IC50 = 18.15 µg/mL) [43].

2.2.2. Antibacterial and Antifungal Activity

Initially, the extract of S. ferrugineus exhibited antifungal and antibacterial activities against Candida albicans, Cladosprorium sphaerospermum, and Staphylococcus aureus. To identify the potential biomolecules from this species that exhibit antifungal and antibacterial activities, the isolated lignans were tested (Figure 3). Among them, lignans 4 and 17 exhibited antifungal and antibacterial activities against S. aureus (MIC = 10 μg/mL and 20 μg/mL, respectively), C. albicans (MIC = 10 μg/mL and 12 μg/mL, respectively), and C. sphaerospermum (MIC = 5 μg/mL and 10 μg/mL, respectively), whereas the other three natural products (5, 18, and 19) only inhibited C. albicans (MIC = 15 μg/mL, 20 μg/mL, and 15 μg/mL, respectively) and S. aureus (MIC = 20 μg/mL, 20 μg/mL, and 20 μg/mL, respectively) [19].
To exploit the antibacterial activity of the aerial parts of S. pohlii, different fractions, especially those extracted using n-hexane, EtOAc, n-BuOH, and methanol, were evaluated against Haemophilus influenzae, Pseudomonas aeruginosa, S. pyogenes, Streptococcus pneumoniae, and Klebsiella pneumoniae. The broth microdilution method was used for measuring the minimum inhibitory concentration (MIC). Among the fractions, the n-hexane fraction exhibited excellent antibacterial activity against Gram-positive S. pneumoniae (MIC = 200 μg/mL). The MIC values of compounds 4 and 17 (400.0 µg/mL) against P. aeruginosa and S. pneumoniae were the best [61].
By conducting the radial growth-inhibition experiment, the antifungal activities of compounds from the bark of S. suberifolius against three plants’ fungal pathogen, namely, Phomopsis cytospore, Fusarium oxysporum, and Alternaria Solani, was exhibited. Compounds 144, 145, and 146 exhibited selective suppressive activities against the tested fungi. Notably, compound 146 was a significantly effective inhibitor of Phomopsis cytospore at 100.0 µg/mL, with an inhibition rate of 86.72% [40].

2.2.3. Antiproliferative and Differentiation Effects

In 2006, Wang’s group found that triterpenoids (111120) isolated from S. tonkinensis inhibit HL-60 cell growth (IC50 = 8.9–99.4 µM). Of note, oleanolic acid 119 acted as the most effective antiproliferative agent (IC50 = 8.9 µg/mL) (Figure 4). Compound 113 exhibited the lowest growth-inhibitory effect. According to the NBT-reduction assay, compound 113 induced HL-60 cell differentiation, as measured in [4].

2.2.4. Anti-Complement Activity

Egonol (4), masutakeside I (10), styraxlignolide A (28), and styraxoside B (101) isolated from S. japonica could inhibit the hemolytic activity of the complement system (IC50 = 33, 166, 123, and 65 µM, respectively) (Figure 5). This finding strongly suggested that the methyl enedioxy group of lignans has a vital role in inhibiting the hemolytic activity of human serum against erythrocytes [22].

2.2.5. Anti-Complement Activity

Natural products isolated from S. japonica were tested for in vitro antioxidant activities through the DPPH radical scavenging test. Among them, 3033 exhibited weak DPPH radical scavenging activities (IC50 = 380, 278, 194, and 260 µM, respectively) (Figure 6) [7]. Moreover, Oliveira et al. reported that the hydroalcoholic extract of S. camporum could concentration-dependently scavenge DPPH radicals; a maximum scavenging activity of 85% was observed at 30.0 µg/mL [11].

2.2.6. Induction of Apoptosis

Lee and Lim revealed that the ethanol extract of S. japonica Siebold et al., Zuccarini (SJSZ) induced programmed cell death (apoptosis) in HepG2 cells under the experimental condition (75.0 µg/mL of SJSZ for 4 h treatment). The results indicated that the ethanol extract of SJSZ (75 µg/mL) stimulates an increase in the number of iROS, Ca2+, and the apoptotic-related factors in HepG2 cells [62].

2.2.7. Induction of Apoptosis

In 2002, a nonradioactive assay was established for measuring aromatase activity by using human ovarian granulosa KGN cells. Lignans 6 and 7 exhibited approximately 1.62- and 1.95-fold increases, respectively, in 17 β-estradiol biosynthesis at 10 µM, and significantly improved 17 β-estradiol biosynthesis by approximately 1.53- and 1.71-fold, respectively, in 3T3-L1 preadipocyte cells (Figure 7). Moreover, egonol gentiotrioside increased serum estrogen levels in ovariectomized rats. These results suggested that these two lignans induce estrogen biosynthesis through the allosteric regulation of aromatase activity [12].

2.2.8. Acetylcholinesterase Inhibitors and Structure–Activity Relationships

In 2011, Liu et al. screened their library of plant extracts through a high-throughput assay. They found that the EtOAc extract of S. agrestis fruits exhibited significant inhibitory activity against AChE. They proved that two active subfractions were responsible for this inhibition and further isolated 13 compounds from the EtOAc extract. Later, they examined the selectivity and inhibitory potency of benzofurans on hAChE, BChE, and EeAChE by using the improved Ellman’s colorimetric method (Figure 8). Some egonol derivatives were synthesized through chemical modifications to clearly understand the structure–activity relationships. According to the results, the inhibition ratio affects the bulkiness and length of the alkyl ester group. In particular, compounds 5053 exhibited inhibitory activity against AChE (IC50 = 1.4–3.1 μM). Compound 50 at 100.0 μM displayed obvious inhibition of Aβ aggregation (77.6%). Liu et al.’s SAR (Structure-Activity Relationships) studies indicated that compounds exhibiting anti-AChE activity are observed with the incorporation of alkyl chains consisting of more than three carbon units, the furan ring, and the ester group. Molecular docking studies proposed a binding site for this class of compound on AChE and identified multiple key residues at the peripheral site that are crucial for mediating the inhibitory effect [10]. The anti-AChE and antifungal activities of two novel polyketides, 156 and 157, were also tested through TLC bioautographic assays. The results indicated that compound 156 could inhibit AChE activity [57].

2.2.9. Inhibitory Effect on Interleukin

Lee and Lim separated a glycoprotein with an approximate molecular mass of 38 kDa from S. japonica. Subsequently, an immunoblot analysis and RT-PCR were conducted to evaluate ERK, JNK, and NF-κB activities and the levels of inflammation-related factors (COX-2, inducible nitric oxide synthase (iNOS), and interleukin (IL)-1β) in Cr-induced BNL CL.2 cells. The SJSZ glycoprotein (50.0 µg/mL) inhibited the expression of ERK, NF-κB, JNK, iNOS, IL-1β, and COX-2 [63].
With further investigation of the SJSZ glycoprotein (38 kDa), Lee and Kim proved that this glycoprotein modulates IFN-γ, IL-2, and IL-12 expression in cyclophosphamide (CTX)-induced Balb/c mice. The glycoprotein counteracted the CTX-induced immunosuppressive effects. It effectively restored the spleen and thymus weights to normal levels and enhanced the phagocytic activity of peritoneal macrophages in response to CTX. Furthermore, the SJSZ glycoprotein exerted regulatory effects on the proliferation of T and B lymphocytes, cytotoxicity of NK cells, and production of key cytokines (IIFN-γ, L-2, and IL-12). Additionally, it improved the activity of antioxidant enzymes (e.g., SOD, CAT, and GPx) [64].

2.2.10. Matrix Metalloproteinase’s Activity

Some triterpenoids (9597, 100) were isolated and further tested the Matrix Metalloproteinases (MMPs)’ activity of the methylene chloride soluble fraction of a methanol extract from the stems of S. japonica. Among them, 95 and 100 displayed effective cytotoxic activities against human dermal fibroblasts (IC50 = 20.0 and 1.12 µM, respectively) (Figure 9). In addition, 96 and 97 exhibited no cytotoxicity for the same cells at the test dose (0.01–1 µM). However, 96 dose-dependently reduced UV-induced MMP-1 protein levels to normal levels by 73.1% at 0.01 µM [65]. In a dose-dependent manner, 96 effectively downregulated MMP-1 protein expression, whereas it upregulated type-1 procollagen protein expression in the UV-irradiated cultured human skin fibroblasts of an elderly person [66].
Styrax japonoside B (26) exerted inhibitory activity against MMP-1 and prevented UV-induced changes in MMP-1 expression. At 10 µM, the treatment led to a significant dose-dependent reduction in MMP-1 protein expression, with an average decrease of 62.1% compared with the vehicle-treated control cells. The findings suggested that the glycoprotein can potentially be used as a potent antimetastatic agent. This glycoprotein exerts its effect by suppressing MMP-9 enzymatic activity through the NF-κB and AP-1 signaling pathways [67].
Two cinnamyl esters (86 and 87) and seven pentacyclic triterpene acids (119 and 125130) in Styrax are the key components that inhibit hCES1A activity. These seven pentacyclic triterpene acids in the two active sites of Styrax exert a significant inhibitory effect on hCES1A (IC50 = 41–478 nM). Among them, epibetulinic acid (129) (IC50 = 0.041 µg/mL), oleanonic acid (125) (IC50 = 0.49 µg/mL), and betulonic acid (126) (IC50 = 1.48 µg/mL) exhibited the strongest inhibitory activity against hCES1A [42,51].

2.2.11. Antiasthmatic, Antiulcer, and Anti-Inflammatory Activities

In a murine asthma model, homoegonol (17) exerted significant effects in reducing inflammatory cell infiltration and Th2 cytokine production in the bronchoalveolar lavage fluid. It also attenuated airway hyperresponsiveness, decreased serum IgE levels, and downregulated iNOS and MMP-9 expression. Thus, compound 17 exhibited the potential to effectively suppress OVA challenge-induced asthmatic responses (Figure 10).
In 2005, the extracted fractions of S. pohlii aerial parts, including the EtOAc fraction, ethanolic extract, and hexane fraction, were evaluated for their inhibitory activities against COX-1 and COX-2. The isolated products were further assessed against COX-1 and COX-2. The results revealed that all crude fractions and isolated products induced weak-to-moderate COX-1 and COX-2 inhibition. Among them, 57 exerted mild COX-1 inhibition, of 35.7% at 30 µM [69].

2.2.12. Other Activity

Through micronucleus and comet assays, Oliveira demonstrated that different doses (250, 500, and 1000 mg/kg body weight) of the S. camporum extract’s compounds 4 and 17 had no genotoxic effect in Swiss mice. Moreover, they were effective in reducing doxorubicin- and methanesulfonate-induced DNA and chromosomal damage [11].
Braguine [69] investigated the EtOAc fractions of S. camporum and S. pohlii and isolated and identified compounds 152155. Upon biological evaluation, they found that the EtOAc fractions, as well as compounds 152 and 155, could separate coupled Schistosoma mansoni adult worms. Additionally, compound 155 killed adult schistosomes in vitro. This research group also observed that homoegonol and homoegonol glucoside exhibited the best results against S. mansoni adult worms [70].
In vitro assessments were conducted to determine the protein tyrosine phosphatase 1B (PTP1B)’s inhibitory activities of compounds from S. japonica stem bark. Among the isolated compounds, 108 and 109 had the highest inhibitory activities (IC50 = 7.8 and 9.3 μM, respectively) [45].
By downregulating NF-κB–DNA binding activity, styraxoside A (148) derived from S. japonica exerted inhibitory effects on the expression of LPS-induced iNOS, COX-2, tumor necrosis factor-α, and IL-1β [45].
Jegosaponins A and B (158 and 159, respectively) exhibited potent hemolytic activity in sheep defibrillation (IC50 = 2.1 and 20.2 µg/mL, respectively) and could improve the performance of PC-3 cells and zebrafish embryos through the identification of a membrane nonpermeable DRAQ7, which is a fluorescent nucleus staining dye [58] (Figure 11).

3. Materials and Methods

Through the search of a variety of online libraries such as Wiley Online Library, PubMed, Scifinder Web, ACS, and Web of Science, a summary of the newly discovered chemicals isolated from the genus styrax and their related biological activities in recent decades was provided. All species names were checked using http://www.theplantlist.org (accessed on 10 May 2023).

4. Conclusions

In summary, the Styrax genus comprises 130 species, and most of the species are extensively used as traditional medicines (Appendix A), particularly in China and Korea. Styrax can be easily collected because of its extensive distribution. All the species of the Styrax family, which were reported regarding the aspects of phytochemistry and pharmacology, were comprehensively summarized. In total, 159 compounds (Appendix B), including lignans, terpenoids, steroids, etc., were isolated from various species. The biological activities of those isolated compounds were subsequently investigated, exhibiting broad bioactivities such as cytotoxic activity, antioxidant activity, antifungal activity, apoptotic activity, anti-inflammation activity, anti-complement activity and so on. Chemical and pharmacological studies on the Styrax genus also proved that its main constituents are lignans and terpenoids. Moreover, several bioactive molecules exhibiting strong pharmacological activities were also isolated from Styrax (Appendix C).
Of note, information about the structure–activity relationships of most bioactive compounds is insufficient due to the lack of derivatives. Therefore, the exploitation of the versatility of the potentially bioactive natural compounds obtained from this genus is in great demand. Moreover, some species used in traditional medicines are still untapped such as S. suberifolius, which is used as a cure for rheumatic arthritis, whereas the modern physiochemical and pharmacological investigations are missing. Furthermore, in-depth pharmacological studies, especially in vivo studies, of the isolated biomolecules should be conducted in the future.

Author Contributions

Conceptualization, D.-D.X. and X.-Y.H.; methodology, Y.Z.; formal analysis, N.Z.; investigation, D.-D.X. and X.-Y.H.; resources, Y.Z.; data curation, D.-D.X.; writing—original draft preparation, D.-D.X. and X.-Y.H.; writing—review and editing, D.-D.X., X.-Y.H. and Y.Z.; visualization, N.Z.; supervision, N.Z.; project administration, Y.Z.; funding acquisition, Y.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Chenguang Program of the Shanghai Education Development Foundation and the Shanghai Municipal Education Commission (22CGA51 to Y.Z.). And the start-up funding from Shanghai University of Traditional Chinese Medicine to Y.Z.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We are extremely appreciative of Wei-Dong Zhang and Jin-Xin Wang from the Second Military Medical University for the helpful discussion.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

MCF-7Metastatic breast adenocarcinoma cell line
MDA-MB-231Human breast cancer cell line
Hep-2Human larynx carcinoma cell line
HeLaHuman cervix carcinoma cell lines
C6Rat glioma cell lines
HL-60Human leukemia cell line
A549Human lung cancer cell line
PC-3Human prostatic cancer cell line
LuLung cancer cell lines
CCK-8Cell Counting Kit-8
ATCC 6305Streptococcus pneumoniae
ATCC 19615Streptococcus pyogenes
ATCC 10211Hemophilus influenzae
ATCC 27853Pseudomonas aeruginosa
ATCC 10031Klebsiella pneumoniae
MICMinimum inhibitory concentration
DPPHDPPH radical
HepG2Hepatocellular carcinoma cell line
KGNHuman ovarian granulosa cells
AChEAcetylcholinesterase
EeAChEElectrophorus electricus AChE
hAChEHuman AChE
BChEButyrylcholinesterase
CTXCyclophosphamide
IFN-γInterferon-γ
hCES1AHuman carboxylesterase 1A1
MMP-1Matrix metalloproteinase-1
PTP1BThe protein tyrosine phosphatase 1B
iNOSNitric oxide synthase
TNF-αTumor necrosis factor-α
IL-1βInterleukin-1β
COX-1Cyclooxygenase-1
COX-2Cyclooxygenase-2
NF-κbNuclear factor-κB

Appendix A

Table A1. Genus Styrax and their traditional use.
Table A1. Genus Styrax and their traditional use.
Genus StyraxTraditional Use
S. perkinsiaeEstrogen synthesis promotion
S. obassiaAnticancer activities
S. japonicaCough, bronchitis, sore throat, inflammation, paralysis, laryngitis, and expectoration treatment
S. pohlii/
S. camporumAntimicrobial, anticancer, antifungal, hypolipidemic, and immunossupressive activities
S. macranthus/
S. officinalisAntiseptic and anti-respiratory disease
S. argentifolius/
S. ferrugineus/
S. agrestis/
S. tonkinensisExpectorant, antiseptic, and analgesic activities
S. suberifoliusRheumatic disease cure
S. ramirezii/

Appendix B

Table A2. Chemical constituents of plants from the genus Styrax.
Table A2. Chemical constituents of plants from the genus Styrax.
No.Compound Class and NameSourceRef.
Lignans
15-(2-Propen-1-one)-7-me-thoxy-2-(3,4-methylenedioxyphenyl) benzofuranS. perkinsiae[18]
21″-Hydryoxyegonol gentiobiosideS. perkinsiae[18]
S. obassia[2]
S. ferrugineus[19]
3Obassioside BS. perkinsiae[18]
S. obassia[2]
S. obassia
S. obassia
[2,60]
4EgonolS. perkinsiae[18]
S. japonica[21,25]
S. obassia[28,31]
S. agrestis[10]
S. ferrugineus[19]
S. pohlii[69]
S. camporum[11]
S. macranthus[32]
S. officinalis L.[35]
S. argentifolius[43]
5Egonol glucosideS. perkinsiae[18]
S. japonica[20]
S. suberifolius[40]
S. macranthus[32]
S. obassia[28]
[60]
6Egonol gentiobiosideS. perkinsiae[17,18]
S. macranthus[32]
S. obassia[2]
S. pohlii[69]
7Egonol gentiotriosideS. perkinsiae[17,18]
S. macranthus[32]
8MasutakesideI (sutakeside I)S. perkinsiae[18]
S. japonica[22]
S. obassia[27]
9trans-5-(3-Hydroxypropyl)-7-methoxy-2-[3-methoxy-4-hydroxyphenyl)-benzofuran-5-yl]benzufuranS. perkinsiae[17]
10(E)-5-(2-Formylvinyl)-7-metho-xy-2-(3,4-methylenedioxyphenyl)benzofuran
S. perkinsiae[17]
115-(3-Butanoyloxypropyl)-7-methoxy-2-(3,4-methylene dioxyphenyl)benzofuranS. perkinsiae[17]
125-(3-Hydroxypropyl)-7-hydroxy-2-(3,4-methylene-dioxyphenyl) benzofuranS. perkinsiae[17]
S. macranthus[32]
125-(3-Hydroxypropyl)-7-hydroxy-2-(3,4-methylene-dioxyphenyl) benzofuranS. perkinsiae[17]
S. macranthus[32]
13Egonol acetateS. perkinsiae[17]
S. japonica[25]
S. obassia[28,29,31]
S. agrestis[10]
S. officinalis L.[37]
14Demethoxy egonol acetateS. perkinsiae[17]
S. japonica[25]
15Styraxlignolide BS. perkinsiae[18]
S. japonica[7]
16Styraxjaponoside CS. perkinsiae[18]
S. japonica[7]
17Nor-lignans5-(3″-hydroxypropyl)-7-methoxy-2-(3′,4′-methylenedioxyphenyl) benzofuranS. ferrugineus[19]
S. camporum[11]
S. pohlii[69]
185-[3″-(β-D-Glucopyranosyloxy)propyl]-7-methoxy-2-(3′,4′-methylenedioxyphenyl) benzofuranS. ferrugineus[19]
S. pohlii[69]
19Dihydrodehydrodiconiferyl alcoholS. ferrugineus[19]
20Styraxjaponoside CS. japonica[21]
21ArctiinS. japonica[21]
22MatairesinosideS. japonica[20,21]
23Pinoresinol-4-O-β-D-glucopyranosideS. japonica[21]
242R-(4′-hydroxy-3′-methoxyphenyl)-6R-(3″,4″-methylenedioxyphenyl)-8-oxo-3,7-dioxabicyclo [3.3.0]octane 4′-hydroxylS. japonica[7]
25Styraxjaponoside AS. japonica[20]
26Styraxjaponoside BS. japonica[20]
27Dihydrodehydrodiconiferyl alcohol 9-O-glucosideS. japonica[20]
28Styraxlignolide AS. japonica[22]
29Styraxlignolide BS. japonica[7]
30Styraxlignolide CS. japonica[7]
31Styraxlignolide DS. japonica[7]
32Styrax lignolides FS. japonica[7,24]
33(–)-Pinoresinol glucosideS. japonica[7]
34Styrlignan AS. japonica[23]
351R,2R,5S,6R-2-(4′-Hydroxy-3′-methoxyphenyl)-6-(3″,4″-dimethoxyphenyl)-3,7-dioxabicyclo-[3.3.0]octane4′-O-β-D-glucopyranosideS. japonica[24]
36Obassioside AS. japonica[26]
37Methyl 3-[7-methoxy-2-(3′,4′-methylene-dioxyphenyl)-5-benzofuranyl]-propionateS. obassia[31]
38Methyl3-[2-(3′,4′-methylen-edioxyphenyl)-5-benzofuranyl]-propionateS. obassia[31]
395-(3″-Propanoyloxypropyl)-7-methoxy-2-(3′,4′-methylenedioxyphenyl)-benzofuranS. obassia[28]
S. agrestis[10]
40Egonol-2-methylbutanoateS. obassia[31]
417-Demethoxylegonol-2-methylbutanoateS. obassia[5]
42Egonol propanoateS. obassia[29]
S. agrestis[10]
433-[7-Methoxy-2-(3,4-methylenedioxyphenyl)benzofuran-5-yl]propyl-3-[7-methoxy-2-(3,4-methylenedioxyphenyl)-benzofuran-5-yl]propanoateS. macranthus[32]
44Demethoxy egonol gentiobiosideS. macranthus[32]
457-Methoxy-2-(3,4-methylenedioxyphenyl)
benzofuran-5-carbaldehyde
S. macranthus[32]
46Demethoxy egonolS. macranthus[32]
S. obassia[28]
S. japonica[23]
475-3″-(2-Methylbutanoyloxy)propyl]-7-methoxy-2-(3′,4′-dimethoxyphenyl) benzofuranS. officinalis L.[23]
485-(3″Benzoyloxypropyl)-7-methoxy-2-(3′,4′-methylenedioxyphenyl)-benzofuranS. officinalis L.[36]
494-[3″-(1c-methylbutanoyloxy)propyl]-2-methoxy-(3′,4′-methylenedioxyphenyl)-1a,5b-dihydrobenzo-[3,4]-cyclobutaoxirene S. officinalis L.[65]
50Egonol-9(Z),12(Z) linoleateS. agrestis[10]
517-Demethoxyegonol-9(Z),12(Z) linoleateS. agrestis[10]
527-Demethoxyegonol oleateS. agrestis[10]
53Egonol oleateS. agrestis[10]
547-Demethoxylegonol acetateS. agrestis[10]
55Egonol-2-methylpropanoatS. agrestis[10]
56(±)SyringaresinolS. camporum[38]
57Homoegonol gentiobioside S. pohlii[39]
58Lariciresinol 4-O-β-D-glucosideS. perkinsiae[39]
59(−)-Secoisolariciresinol 4-O-β-D-GlucopyranosideS. perkinsiae[39]
60Lariciresinol4′-O-β-D-glucosideS. perkinsiae[39]
61Lanicepside AS. perkinsiae[39]
62Solariciresinol4-O-β-D-glucopyranosideS. perkinsiae[39]
63(+)-Lariciresinol9-O-β-D-glucopyranosideS. perkinsiae[39]
642R,3S-Dihydrodehydrodiconiferyl alcohol 4′-O-β-D-glucopyranosideS. perkinsiae[39]
65PinoresinolS. perkinsiae[39]
66Homoegonol glucosideS. suberifolius[40]
672-(4-Hydroxy3-methoxyphenyl)-5-(3-hydroxypropyl)-7-methoxybenzofuranS. suberifolius[40]
682-(3-Hydroxy-4-methoxyphenyl)-7-methoxy-5benzofuranpropanolS. suberifolius[40]
69(+)-CedrusinS. suberifolius[40]
70(−)-(7R,8S)-Dihydrodehydrodiconiferyl alcoholS. suberifolius[40]
71(−)-(7R,8S)-Dihydrodehydrodiconiferyl alcohol 4-O-β-DglucopyranosideS. suberifolius[40]
72(−)-(7S,8R)-Dihydrodehydrodiconiferylalcohol 4-O-β-D-glucopyranosideS. suberifolius[40]
73(+)-(7S,8R)-Dihydrodehydrodiconiferyl alcoholS. suberifolius[40]
74(+)-(7S,8R)-Erythro-4,7,9,9′-tetrahydroxy-3,3′-dimethoxy-8-O-4′-neolignanS. suberifolius[40]
75(−)-Symplocosneolignan AS. suberifolius[40]
76(−)-7-O-Ethylguaiacylglycerol (15)S. suberifolius[40]
772[4-(3-Hydroxypropyl)-2-methoxyphenoxy]-1,3-propanediolS. suberifolius[40]
78Dihydroconiferyl alcoholS. suberifolius[40]
793,3-Bis(3,4-dihydro-6-methoxy-2H-1-benzopyranS. tonkinensis[41]
80Rac-(8α,8′β)-4,4′-dihydroxy3,3′-dimethoxylignan-9,9′-diyldiacetateS. tonkinensis[41]
81(–)-SecoisolariciresinoS. tonkinensis[41]
824,4′-Dihydroxy-3,3′dimethoxy-9-ethoxy-9,9′-epoxylignanS. tonkinensis[41]
83(2S,3R,4R)-4-[1-Ethoxy-1-(4-hydroxy-3-methoxy)phenyl]methyl-2(4-hydroxy-3-methoxy)phenyl-3-hydroxymethyl-tetrahydrofuranS. tonkinensis[41]
84(–)-Neo-olivil-(9-O-9″)-seco-isolariciresinolS. tonkinensis[41]
85IsolariciresinolS. tonkinensis[41]
86Stytonkinol AS. tonkinensis[42]
87Stytonkinol BS. tonkinensis[42]
88StyraxinS. argentifolius[43]
89Vladinol DS. argentifolius[43]
905-Carboxy7-methoxy-2-(3′,4′-methylenedioxyphenyl)benzofuranS. argentifolius[43]
915-((E)-2-Carboxyvinyl)-7-methoxy-2-(3′,4′-methylenedioxyphenyl)benzofuranS. argentifolius[43]
92(–)-MachicendiolS. argentifolius[43]
93MachicendonaS. argentifolius[43]
Terpenoids
94TaraxerolS. japonica[7,45]
95Oleanolic aldehyde acetateS. japonica[22,54]
96Erythrodiol-3-acetateS. japonica[22,54]
97EuphorginolS. japonica[22,54]
983β-Acetoxyolean-12-en-28-acidS. japonica[45]
993β-Acetoxy-17β-hydroxy-28-norolean-12-eneS. japonica[45]
100Anhydrosophoradiol-3-acetateS. japonica[22,54]
101Styraxosides BS. japonica[44]
102CamellenodiolS. japonica[44]
103Jegosaponins AS. japonica[46]
104Jegosaponins BS. japonica[46]
105Jegosaponins CS. japonica[46]
106Jegosaponins DS. japonica[46]
1073β-Acetoxy-28-hydroxyolean-12-eneS. japonica[47]
1083β-Acetoxyolean-12-en-28-acidS. japonica[47]
1093β-Acetoxyolean-12-en-28-aldehydeS. japonica[47]
1103β-Acetoxy-17β-hydroxy-28-norolean-12-eneS. japonica[47]
1116β-Hydroxy-3-oxo-11α,12α-epoxyolean-
28,13β-olide
S. tonkinensis[4]
1123β,6β-Dihydroxy-11α,12α-epoxyolean-28,13β-olideS. tonkinensis[4]
1133β,6β-Dihydroxy-11-oxo-olean-12-en-28-oic acidS. tonkinensis[4]
1143β-Hydroxy-12-oxo-13HR-olean-28,19β-olideS. tonkinensis[4]
11519β-Hydroxy-3-oxo-olean-12-en-28-oic acidS. tonkinensis[4]
1166β-Hydroxy-3-oxo-olean-12-en-28-oic acidS. tonkinensis[4]
117Sumaresinolic acidS. tonkinensis[4,51]
118Siaresinolic acidS. tonkinensis[4,51]
119Oleanolic acidS. tonkinensis[4,51]
12021-Benzoylbarringtogenol CS. officinalis L.[4]
121Styrax-saponin AS. officinalis L.[49]
122Styrax-saponin BS. officinalis L.[49]
123Styrax-saponin CS. officinalis L.[49]
124DeacylsaponinS. officinalis L.[49]
125Oleanonic acidS. tonkinensis[42,51]
126Betulonic acidS. tonkinensis[42,51]
127Corosolic acidS. tonkinensis[42,51]
128Maslinic acidS. tonkinensis[42,51]
129Epibetulinic acidS. tonkinensis[42]
130Betulinic acidS. tonkinensis[42,51]
1312α,3α,24-trihydroxy-urs-12-en-28-oic acidS. argentifolius[43]
Aromatic Compounds
132trans-(Tetrahydro-2-(4-hydroxy-3-methoxyphenyl)-5-oxofuran-3-yl)methylbenzoateS. tonkinensis[52]
1333-(4-Hydroxy-3-methoxyphenyl)-2-oxopropylbenzoateS. tonkinensis[52]
1344-(E)-3-Ethoxyprop-1-enyl)-2-methoxyphenolS. tonkinensis[52]
135Benzoic acidS. tonkinensis[52]
136VanillinS. tonkinensis[52]
137DehydrodivanillinS. tonkinensis[52]
138Vanillic acidS. tonkinensis[52]
139Coniferyl aldehydeS. tonkinensis[52]
140MethylsyringinS. japonica[21]
141SyringinS. japonica[7,21]
142IsotachiosideS. perkinsiae[39]
143(2R,3R)-3,7,4′-Trihydroxy-5,3′-dimethoxyflavan 7-O-β-D-glucopyranosideS. suberifolius[40]
144Methyl orsellinateS. suberifolius[40]
145Ethyl orsellinateS. suberifolius[40]
146Methyl β-orcinolcarboxylateS. suberifolius[40]
Steroids
147StigmasterolS.macranthus[32]
148Styraxosides AS. japonica[32]
149DaucosterolS.macranthus[32]
150β-SitosterolS. perkinsiae[17]
151(20R)-24Ethylcholest-5,22-dien-7-oneS. argentifolius[43]
Others
152Kaempferol-3-O-(2″,4″-di-O-(E)-p-coumaroyl-β-D-glucopyranoside)S. pohlii[56]
S. camporum[56]
153Kaempferol-3-O-(2″,6″-di-O-(E)-p-coumaroyl)-β-D-glucopyranosideS. pohlii[56]
S. camporum[56]
154QuercetinS. pohlii[56]
S. camporum[57]
155KaempferolS. pohlii[56]
S. camporum[57]
156
157
Koninginin T
Koninginin U
S. pohlii[57]
S. pohlii[57]
158Jegosaponins AS. japonica[58]
159Jegosaponins BS. japonica[58]

Appendix C

Table A3. Structural information of the active molecule.
Table A3. Structural information of the active molecule.
No.StructurePhytochemistryPharmacological Activity
3Pharmaceuticals 16 01043 i001S. perkinsiae
S. obassia
MCF-7 (IC50 = 53.5 μg/mL)
Hela (IC50 = 23.3 μg/mL)
HL-60 (IC50 = 16.8 μg/mL)
4Pharmaceuticals 16 01043 i002S. perkinsiae
S. japonica
S. obassia
S. agrestis
S. ferrugineus
S. pohlii
S. camporum
S. macranthus
S. officinalis
S. argentifolius
Hep-2 (IC50 = 3.6 μg/mL)
C6 (IC50 = 3.2 μg/mL)
KB (IC50 = 22.11 μg/mL)
HepG2 (IC50 = 18.15 μg/mL)
Lu (IC50 = 21.50 μg/mL)
Hemolytic activity (IC50 = 33 μg/mL)
C. sphaerospermum (MIC = 5 mg/mL)
C. albicans (MIC = 10 μg/mL)
S. aureus (MIC = 10 μg/mL)
ATCC 27853 and ATCC 6305 (MIC = 400 mg/mL)
COX-1 (inhibition rate = 35.7% at 30 μM)
Reduce doxorubicin- and methanesulfonate-induced
DNA and chromosomal damage
5Pharmaceuticals 16 01043 i003S. perkinsiae
S. japonica
S. suberifolius
S. macranthus
S. obassia
MCF-7 (IC50 = 27.9 μg/mL)
Hela (IC50 = 23.3 μg/mL)
S. aureus (MIC = 20 μg/mL)
C. albicans (MIC = 15 μg/mL)
HL-60 (IC50 = 47.8 μg/mL)
6Pharmaceuticals 16 01043 i004S. perkinsiae
S. macranthus
S. obassia
S. pohlii
Estrogen biosynthesis
7Pharmaceuticals 16 01043 i005S. perkinsiae
S. macranthus
Estrogen biosynthesis
10Pharmaceuticals 16 01043 i006S. perkinsiaeHemolytic activity (IC50 = 166 μg/mL)
11Pharmaceuticals 16 01043 i007S. perkinsiaeMCF-7 (IC50 = 5.5 μg/mL)
MDA-MB-231 (IC50 = 3.81 μg/mL)
14Pharmaceuticals 16 01043 i008S. perkinsiae
S. japonica
MCF-7 (IC50 = 15.0 μg/mL)
MDA-MB-231 (IC50 = 13.71 μg/mL)
17Pharmaceuticals 16 01043 i009S. ferrugineus
S. camporum
S. pohlii
HeLa (IC50 = 5.3 μg/mL)
C6 (IC50 = 4.9 μg/mL)
C. sphaerospermum (MIC = 10 μg/mL)
C. albicans (MIC = 12 μg/mL)
S. aureus (MIC = 10 μg/mL)
Th2 cytokines, iNOS, MMP-9
Reduce doxorubicin- and methanesulfonate-induced
DNA and chromosomal damage
18Pharmaceuticals 16 01043 i010S. ferrugineus
S. pohlii
S. aureus (MIC = 20 μg/mL)
C. albicans (MIC = 20 μg/mL)
19Pharmaceuticals 16 01043 i011S. ferrugineusS. aureus (MIC = 20 μg/mL)
C. albicans (MIC = 15 μg/mL)
26Pharmaceuticals 16 01043 i012S. japonicaMMP-1 (inhibition rate = 62.1% at 10 μM)
28Pharmaceuticals 16 01043 i013S. japonicaHemolytic activity (IC50 = 123 μg/mL)
30Pharmaceuticals 16 01043 i014S. japonicaDPPH (IC50 = 380 μM)
31Pharmaceuticals 16 01043 i015S. japonicaDPPH (IC50 = 278 μM)
32Pharmaceuticals 16 01043 i016S. japonicaDPPH (IC50 = 194 μM)
33Pharmaceuticals 16 01043 i017S. japonicaDPPH (IC50 = 260 μM)
50Pharmaceuticals 16 01043 i018S. agrestisEeAChE (IC50 = 1.4 μg/mL)
hAChE (IC50 = 1.7 μg/mL)
51Pharmaceuticals 16 01043 i019S. agrestisEeAChE (IC50 = 2.0 μg/mL)
hAChE (IC50 = 2.7 μg/mL)
52Pharmaceuticals 16 01043 i020S. agrestisEeAChE (IC50 = 1.4 μg/mL)
hAChE (IC50 = 1.8 μg/mL)
53Pharmaceuticals 16 01043 i021S. agrestisEeAChE (IC50 = 2.2 μg/mL)
hAChE (IC50 = 3.1 μg/mL)
86Pharmaceuticals 16 01043 i022S. tonkinensisHela (IC50 = 26.75 μM)
MCF-7 (IC50 = 45.16 μM)
87Pharmaceuticals 16 01043 i023S. tonkinensisMCF-7 (IC50 = 57.1 μM)
Hemolytic activity (IC50 = 65 μg/mL)
92Pharmaceuticals 16 01043 i024S. argentifoliusKB (IC50 = 96.01 μg/mL)
HepG2 (IC50 = 86.60 μg/mL)
Lu (IC50 = 106.86 μg/mL)
95Pharmaceuticals 16 01043 i025S. japonicaHuman dermal fibroblasts (IC50 = 20 μM)
96Pharmaceuticals 16 01043 i026S. japonicaMMP-1 (inhibition rate = 73.1% at 0.01 μM)
100Pharmaceuticals 16 01043 i027S. japonicaHuman dermal fibroblasts (IC50 = 1.12 μM)
101Pharmaceuticals 16 01043 i028S. tonkinensisHemolytic activity (IC50 = 65 μg/mL)
108Pharmaceuticals 16 01043 i029S. japonicaPTP1B (IC50 = 7.8 μg/mL)
109Pharmaceuticals 16 01043 i030S. japonicaPTP1B (IC50 = 9.3 μg/mL)
112Pharmaceuticals 16 01043 i031S. tonkinensisHL-60 (IC50 = 27.5 μg/mL)
116Pharmaceuticals 16 01043 i032S. tonkinensisHL-60 (IC50 = 14.2 μg/mL)
118Pharmaceuticals 16 01043 i033S. tonkinensisHL-60 (IC50 = 29.0 μg/mL)
119Pharmaceuticals 16 01043 i034S. tonkinensisHL-60 (IC50 = 8.9 μg/mL)
125Pharmaceuticals 16 01043 i035S. tonkinensishCES1A (IC50 = 0.49 mg/mL)
126Pharmaceuticals 16 01043 i036S. tonkinensishCES1A (IC50 = 1.48 μg/mL)
129Pharmaceuticals 16 01043 i037S. tonkinensishCES1A (IC50 = 0.041 μg/mL)
144Pharmaceuticals 16 01043 i038S. suberifoliusA. solani (inhibition rate = 58.41% at 100 μg/mL)
F. oxysporum (inhibition rate = 67.39% at 100 μg/mL)
145Pharmaceuticals 16 01043 i039S. suberifoliusA. solani (inhibition rate = 59.31% at 100 μg/mL)
F. oxysporum (inhibition rate = 45.65% at 100 μg/mL)
146Pharmaceuticals 16 01043 i040S. suberifoliusF. oxysporum (inhibition rate = 61.41% at 100 μg/mL)
P. cytospore (inhibition rate = 86.72% at 100 μg/mL)
149Pharmaceuticals 16 01043 i041S.macranthusiNOS, COX-2, TNF-a, and IL-1b
152Pharmaceuticals 16 01043 i042S. pohlii
S. camporum
Separate coupled Schistosoma mansoni adult worms
155Pharmaceuticals 16 01043 i043S. pohlii
S. camporum
Separate coupled Schistosoma mansoni adult worms
Kill adult schistosomes
156Pharmaceuticals 16 01043 i044S. pohliiAChE
158Pharmaceuticals 16 01043 i045S. japonicaHemolytic activity (IC50 = 2.1 μg/mL)
159Pharmaceuticals 16 01043 i046S. japonicaHemolytic activity (IC50 = 20.2 μg/mL)

References

  1. Fritsch, P.W.; Almeda, F.; Renner, S.S.; Martins, A.B.; Cruz, B.C. Phylogeny and circumscription of the near-endemic Brazilian tribe Microlicieae (Melastomataceae). Am. J. Bot. 2004, 91, 1105–1114. [Google Scholar] [CrossRef]
  2. Pauletti, P.M.; Teles, H.L.; Silva, D.H.S.; Araújo, A.R.; Bolzani, V.S. The Styracaceae. Rev. Bras. Farmacogn. 2006, 16, 576–590. [Google Scholar] [CrossRef] [Green Version]
  3. Jiang, S. Dictionary of Chinese Materia Medical; Shanghai Scientific and Technical Publishing House: Shanghai, China, 1997; pp. 1723–1725. [Google Scholar]
  4. Wang, F.; Hua, H.; Pei, Y.; Chen, D.; Jing, K.Y. Triterpenoids from the Resin of Styrax tonkinensis and Their Antiproliferative and Differentiation Effects in Human Leukemia HL-60 Cells. J. Nat. Prod. 2006, 69, 807–810. [Google Scholar] [CrossRef] [PubMed]
  5. Lee, T.B. Illustrated Flora of Korea; Hwang Mun Sa: Seoul, Republic of Korea, 1982; p. 614. [Google Scholar]
  6. Kitagawa, I.; Imakura, Y.; Hayashi, T.; Yosioka, I. Structure of deacyl-jegosaponin, a common deacyl derivative of jegosaponin isolated from pericarps of Styrax japonica Sieb. et Zucc. Chem. Pharm. Bull. 1974, 22, 1675–1677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Min, B.S.; Na, M.K.; Oh, S.R.; Ahn, K.S.; Jeong, G.S.; Li, G.; Lee, S.K.; Joung, H.; Lee, H.K. New Furofuran and Butyrolactone Lignans with Antioxidant Activity from the Stem Bark of Styrax japonica. J. Nat. Prod. 2004, 67, 1980–1984. [Google Scholar] [CrossRef] [PubMed]
  8. He, L.; Zhou, Y.; Wan, G.J.; Wang, W.C.; Zhang, N.; Yao, L. Antinociceptive effects of flower extracts and the active fraction from Styrax japonicus. J. Ethnopharmacol. 2022, 284, 114779–114788. [Google Scholar] [CrossRef]
  9. Xie, Z.W. Compilation of Chinese Herbal Medicine; People’s Medical Publishing House: Beijing, China, 1975. [Google Scholar]
  10. Liu, J.; Dumontet, V.; Simonin, A. Benzofurans from Styrax agrestis as acetylcholinesterase inhibitors: Structure–activity relationships and molecular modeling studies. J. Nat. Prod. 2011, 74, 2081–2088. [Google Scholar] [CrossRef]
  11. Francielli de Oliveira, P.; Furtado, R.A.; Acésio, N.O.; Leandro, L.F.; Montanheiro, G.; de Padua, F.C.; Correa, M.B.; Braguini, C.G.; Pauletti, P.M.; Tavares, D.C. In Vivo Protective Activity of Styrax camporum Hydroalcoholic Extract against Genotoxicity Induced by Doxorubicin and Methyl Methanesulfonate in the Micronucleus and Comet Assays. Planta Med. 2012, 78, 1899–1905. [Google Scholar] [CrossRef]
  12. Lu, D.; Yang, L.; Li, Q.L.; Gao, X.P.; Wang, F.; Zhang, G.L. Egonol gentiobioside and egonol gentiotrioside from Styrax perkinsiae promote the biosynthesis of estrogen by aromatase. Eur. J. Pharmacol. 2012, 691, 275–282. [Google Scholar] [CrossRef]
  13. Zhang, Y.; Zhao, X.C.; Xie, Y.G.; Fan, C.; Huang, Y.Y.; Yan, S.K.; Zhang, Y.; Jin, H.Z.; Zhang, W.D. Eight new γ-lactam alkaloids from the roots of the Hemerocallis minor Mill. Fitoterapia 2017, 118, 80–86. [Google Scholar] [CrossRef]
  14. Xie, Q.; Wu, G.Z.; Yang, N.; Shen, Y.H.; Tang, J.; Zhang, W.D. Delavatine A, an unusual isoquinoline alkaloid exerts anti-inflammation on LPS-induced proinflammatory cytokines production by suppressing NF-κB activation in BV-2 microglia. Biochem. Biophys. Res. Commun. 2018, 502, 202–208. [Google Scholar] [CrossRef] [PubMed]
  15. Zhao, J.; Zhao, Q.; Lu, J.Z.; Ye, D.; Mu, S.; Yang, X.D.; Zhang, W.D.; Ma, B.L. Natural Nano-Drug Delivery System in Coptidis rhizoma Extract with Modified Berberine Hydrochloride Pharmacokinetics. Int. J. Nanomed. 2021, 16, 6297–6311. [Google Scholar] [CrossRef]
  16. Yuan, W.L.; Huang, Z.H.; Li, B.; Xiao, S.J.; Shen, X.P.; He, Y.Q.; Zhang, W.D.; Shen, Y.H. Trisecocycloartane triterpene dilactones from the cones of Pseudolarix amabilis. Phytochem. Lett. 2021, 45, 88–92. [Google Scholar] [CrossRef]
  17. Li, Q.; Guo, Y.; He, X.; Li, G. Bifunctional Cu(II)-containing PDA-PEI copolymer dots: Demonstration of a dual-mode platform for colorimetric-fluorescent detection of glyphosate in the environment. Talanta 2023, 265, 124865. [Google Scholar] [CrossRef]
  18. Chen, Q.F.; Chen, X.Z.; Li, G.Y.; Wang, C.; Zhang, G.L. Two new 2-phenylbenzofurans from the bark of Styrax perkinsiae. Chin. J. Nat. Med. 2012, 10, 92–97. [Google Scholar] [CrossRef]
  19. Pauletti, P.M.; Araújo, A.R.; Young, M.C.M.; Giesbrecht, A.M.; Bolzani, V.D.S. nor-Lignans from the leaves of Styrax ferrugineus (Styracaceae) with antibacterial and antifungal activity. Phytochemistry 2000, 55, 597–601. [Google Scholar] [CrossRef] [PubMed]
  20. Kim, M.; Moon, H.; Chung, J.H.; Moon, Y.H.; Hahm, K.; Woo, E. Matrix metalloproteinase-1 inhibitor from the stem bark of Styrax japonica S. et Z. Chem. pharm. Bull. 2004, 52, 1466–1469. [Google Scholar] [CrossRef] [Green Version]
  21. Kim, M.; Moon, H.T.; Lee, D.G.; Woo, E.R. A new lignan glycoside from the stem bark of Styrax japonica S. et Z. Arch. Pharm. Res. 2007, 30, 425–430. [Google Scholar] [CrossRef]
  22. Min, B.; Oh, S.; Ahn, K. Anti-complement activity of norlignans and terpenes from the stem bark of Styrax japonica. Planta Med. 2004, 70, 1210–1215. [Google Scholar] [CrossRef]
  23. Wu, N.; Wang, L.; Chzn, Y.; Liao, Z.; Yang, G.Y.; Hu, Q.F. Lignans from the Stem of Styrax japonica. Asian J. Chem. 2011, 23, 931–932. [Google Scholar]
  24. KwanKwonwon, Y.; UnKim, S. Phytochemical studies on seeds of Styrax japonica Sieb. et Zucc. J. Appl. Biol. Chem. 2002, 45, 28–30. [Google Scholar]
  25. Hung, T.M.; Lee, M.K.; Min, B.; Kim, J.C.; Choi, J.S.; Lee, H.K. Two Lignans from the stem bark of Styrax japonica. J. Korean Soc. Appl. Biol. 2009, 52, 560–563. [Google Scholar] [CrossRef]
  26. Kinoshita, T.; Haga, Y.; Narimatsu, S. New nor-neolignan glycosides from Styrax obassla (Styracaceae). Heterocycles 2005, 65, 1471–1480. [Google Scholar] [CrossRef]
  27. Takanashi, M.; Takizawa, Y. New Egonol Glycoside Having D-Xylose, from Immature Seeds of Styrax obassia Sieb. et Zucc. J. Oleo Sci. 2002, 51, 423–426. [Google Scholar] [CrossRef] [Green Version]
  28. Takanashi, M.; Takizawa, Y. New benzofurans related to egonol from immature seeds of Styrax obassia. Phytochemistry 1988, 27, 1224–1226. [Google Scholar] [CrossRef]
  29. Takanashi, M.; Takizawa, Y.; Mitsuhashi, T. Determination of Mercury by Direct Heating of Mercury-Adsorbed Ion-Exchange Resin in Electrothermal Atomic Absorption Spectrometr. Chem. Lett. 1974, 8, 869–871. [Google Scholar] [CrossRef] [Green Version]
  30. Park, S.Y.; Lee, H.; Lee, O.; Kang, H.; Choi, D.H.; Paik, K.H.; Khan, M. Benzofurans from the Seeds of Styrax obassia. Bull. Korean Chem. Soc. 2007, 28, 1874. [Google Scholar]
  31. Lee, H.J.; Park, S.Y.; Lee, O.K.; Jo, H.J.; Kang, H.Y.; Choi, D.H.; Paik, K.H.; Khan, M. Benzofurans and sterol from the seeds of Styrax obassia. Chem. Nat. Compd. 2008, 44, 435–439. [Google Scholar] [CrossRef]
  32. Luo, Y.; He, Z.; Li, H. 2-Aryl benzofurans and their derivatives from seeds of Styrax macranthus. Fitoterapia 2007, 78, 211–214. [Google Scholar] [CrossRef]
  33. Schneiders, G.E.; Stevenson, R. Synthesis of (.+-.)-machicendiol. J. Org. Chem. 1979, 44, 4710–4711. [Google Scholar] [CrossRef]
  34. Anil, H. Four benzofurans glycosides from Styrax officinalis. Phytochemistry 1980, 19, 2784–2786. [Google Scholar] [CrossRef]
  35. Akgul, Y.Y.; Anil, H. Benzofuran from seeds of Styrax officinalis. Fitoterapia 2003, 74, 743–745. [Google Scholar] [CrossRef] [PubMed]
  36. Akgul, Y.Y.; Anil, H. Benzofurans and another constituent from seeds of Styrax officinalis. Phytochemistry 2003, 63, 939–943. [Google Scholar] [CrossRef] [PubMed]
  37. Bacchi, E.M.; Sertie, J.A.; Villa, N.; Katz, H. Antiulcer action and toxicity of Styrax camporum and Caesalpinia ferrea. Planta Med. 1995, 61, 204–207. [Google Scholar] [CrossRef] [PubMed]
  38. Teles, H.L.; Hemerly, J.P.; Pauletti, P.M. Cytotoxic lignans from the stems of Styrax camporum (Styracaceae). Nat. Prod. Res. 2005, 19, 319–323. [Google Scholar] [CrossRef]
  39. Zhang, P.Z.; Zhang, Y.M. Tetrahydrofuranoid Lignans from Stem Bark of Styrax perkinsiae. Chin. J. Exp. Tradit. Med. Formulae 2015, 21, 91–94. [Google Scholar]
  40. Liu, B.L.; Ding, W.B.; Huang, S.Y.; Sun, W.H.; Li, Y.Z. Chemotaxonomic significance of phenylpropanoids from Styrax suberifolius Hook. Et Arn. Biochem. Syst. Ecol. 2018, 78, 35–38. [Google Scholar] [CrossRef]
  41. Hu, W.L.; Li, Z.L.; Chen, Q.J.; Sun, Y.W.; Zhai, S.; Lu, F.; Zhang, C.F. Triterpenes and lignans from the leaves of Styrax tonkinensis. Biochem. Systemat. Ecol. 2019, 86, 103891. [Google Scholar] [CrossRef]
  42. Wang, F.; Zhang, L.; Zhang, Q.; Chen, A.; Wang, S.M.; Fang, Z.F. Two new phenylpropanoids from the resin of Styrax tonkinensis (Pierre) Craib ex Hartw. J. Nat. Med. 2020, 74, 819–824. [Google Scholar] [CrossRef]
  43. Tra, N.T.; Tuyen, N.V.; Cuong, P.V.; Ha, N.T.T.; Anh, L.T.T.; Son, T.N. Chemical constituents from the leaves of Styrax argentifolius H.L. Li and their biological activities. Phytochem. Lett. 2021, 41, 70–73. [Google Scholar] [CrossRef]
  44. Moon, H.; Kim, M.; Woo, E.; Chung, J.H. Triterpenoid from Styrax japonica SIEB. et ZUCC, and its effects on the expression of matrix metalloproteinases-1 and type 1 procollagen caused by ultraviolet irradiated cultured primary human skin fibroblasts. Biol. Pharm. Bull. 2005, 28, 2003–2006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Yun, K.; Min, B.; Kim, J.; Lee, K.T. Styraxoside A isolated from the stem bark of Styrax japonica inhibits lipopolysaccharide-induced expression of inducible nitric oxide synthase and cyclooxygenase-2 in RAW 264.7 cells by suppressing nuclear factor-kappa B activation. Biol. Pharm. Bull. 2007, 30, 139–144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Yoshikawa, K.; Hirai, H.; Tanaka, M. Antisweet Natural Products. XV. Structures of Jegosaponins AD from Styrax japonica SIEB. et Zucc. Chem. Pharm. Bull. 2000, 48, 1093–1096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Kwon, J.H.; Chang, M.J.; Seo, H.W.; Lee, J.H.; Min, B.S.; Na, M.; Kim, J.C.; Woo, M.H.; Choi, J.S.; Lee, H.K. Triterpenoids and a sterol from the stem-bark of Styrax japonica and their protein tyrosine phosphatase 1B inhibitory activities. Phytother. Res. 2008, 22, 1303–1306. [Google Scholar] [CrossRef] [PubMed]
  48. Anil, H. 21-Benzoyl-barringtogenol C, a sapogenin from Styrax officinalis. Phytochemistry 1979, 18, 1760–1761. [Google Scholar] [CrossRef]
  49. Yayla, Y.; Alankuş-Çalışkan, Ö.; Anıl, H.; BBates, R.; Stessman, C.; Kane, V. Saponins from Styrax officinalis. Fitoterapia 2002, 73, 320–326. [Google Scholar] [CrossRef]
  50. Tayoub, G.; Schwob, I.; Bessiere, J.; Masotti, V.; Rabier, J.; Ruzzier, M.; Viano, J. Composition of volatile oils of Styrax (Styrax officinalis L.) leaves at different phenological stages. Biochem. Syst. Ecol. 2006, 34, 705–709. [Google Scholar] [CrossRef]
  51. Wang, L.; Guan, X.Q.; He, R.J.; Huo, P.C.; Qin, W.W.; Cui, L.T.; Hu, Q.; Hou, J.; Mamat, M.; Jia, S.N.; et al. Discovery and characterization of pentacyclic triterpenoid acids in Styrax as potent and reversible pancreatic lipase inhibitors. J. Funct. Foods 2020, 74, 104159. [Google Scholar] [CrossRef]
  52. Wang, F.; Hua, H.; Bian, X.; Pei, Y.H.; Jing, K.Y. Two new aromatic compounds from the resin of Styrax tonkinensis (Pier.) Craib. J. Asian Nat. Prod. Res. 2006, 8, 137–141. [Google Scholar] [CrossRef]
  53. Wang, F.; Fang, Z.F. Chemical Constituents from Resin of Styrax tonkinensis. Chin. J. Exp. Tradi. Med. Formulae 2012, 18, 17. [Google Scholar]
  54. Kim, M.; Lee, H.; Hahm, K.; Moon, Y.H.; Woo, E. Pentacyclic triterpenoids and their cytotoxicity from the stem bark of Styrax japonica S. et Z. Arch. Pharm. Res. 2004, 27, 283–286. [Google Scholar] [CrossRef]
  55. Vardar, Y.; Oflas, S. Preliminary studies on the Styrax oil. Qual. Plant. Mater. Veg. 1973, 22, 145–148. [Google Scholar] [CrossRef]
  56. Braguine, C.G.; Bertanha, C.S.; Gonçalves, U.O.; Magalhães, L.G.; Rodrigues, V.; Gimenez, V.M.M. Schistosomicidal evaluation of flavonoids from two species of Styrax against Schistosoma mansoni adult worms. Pharm. Biol. 2012, 50, 925–929. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Biasettoa, C.R.; Somensia, A.; Sordia, R.; Chaplab, V.M.; Ebrahimic, S.N.; Silvad, G.H.; Telese, H.L.; Bolzania, V.S.; Youngf, M.C.M.; Pfenningg, L.H.; et al. The new koninginins T-U from Phomopsis stipata, an endophytic fungus isolated from Styrax camporum Pohl. Phytochem. Lett. 2020, 36, 106–110. [Google Scholar] [CrossRef]
  58. Nishimura, M.; Fuchino, H.; Takayanagi, K.; Kawakami, H.; Nakayama, H.; Kawahara, H.; Shimada, Y. Toxicity of Jegosaponins A and B from Styrax japonica Siebold et al., Zuccarini in Prostate Cancer Cells and Zebrafish Embryos Resulting from Increased Membrane Permeability. Int. J. Mol. Sci. 2021, 22, 6354. [Google Scholar] [CrossRef]
  59. Francielli de Oliveira, P.; Damasceno, J.L.; Bertanha, C.S.; Bertanha, C.S.; Araujo, A.R.B.; Pauletti, P.M.; Tavares, D.C. Study of the cytotoxic activity of Styrax camporum extract and its chemical markers, egonol and homoegonol. Cytotechnology 2016, 68, 1597–1602. [Google Scholar] [CrossRef] [Green Version]
  60. Cao, T.Q.; Lee, B.M.; Jung, Y.W.; Nguyen, V.T.; Kim, J.A.; Min, B.S. Cytotoxic Activity of Compounds from Styrax obassia. Nat. Prod. Commun. 2017, 12, 259–260. [Google Scholar] [CrossRef]
  61. Bertanha, C.S.; Utrera, S.H.; Gimenez, V.M.M.; Groppo, M.; Silva, M.; Cunhua, W.R.; Martins, C.H.G.; Januário, A.H.; Pauletti, P.M. Antibacterial evaluation of Styrax pohlii and isolated compounds. Braz. J. Med. Biol. Res. 2013, 49, 653–658. [Google Scholar] [CrossRef] [Green Version]
  62. Lee, J.; Lim, K. Apoptotic activity of ethanol extract from Styrax Japonica Siebold et al. Zuccarini in HepG2 cells. J. Ethnopharmacol. 2010, 131, 210–215. [Google Scholar] [CrossRef]
  63. Lee, J.; Lim, K. Inhibitory effect of Styrax Japonica Siebold et al., Zuccarini glycoprotein (38 kDa) on interleukin-1β and induction proteins in chromium (VI)-treated BNL CL. 2 cells. Mol. Cell Biochem. 2012, 367, 103–111. [Google Scholar] [CrossRef]
  64. Lee, J.; Lim, K. SJSZ glycoprotein (38 kDa) modulates expression of IL-2, IL-12, and IFN-γ in cyclophosphamide-induced Balb/c. Inflamm. Res. 2012, 61, 1319–1328. [Google Scholar] [CrossRef] [PubMed]
  65. Schreiber, F.G.; Stevenson, R. Synthesis of benzofuran Styrax extractives. J. Chem. Soc. Perkin Trans. 1976, 1, 1514–1518. [Google Scholar] [CrossRef]
  66. Moon, H.; Lee, J.; Chung, J.H. The effect of erythrodiol-3-acetate on the expressions of matrix metalloproteinase-1 and type-1 procollagen caused by ultraviolet irradiated cultured primary old aged human skin fibroblasts. Phytomedicine 2006, 13, 707–711. [Google Scholar] [CrossRef] [PubMed]
  67. Lee, J.; Lim, K. Inhibitory effect of phytoglycoprotein (38 kDa) on expression of matrix metalloproteinase-9 in 12-O-tetradecanoylphorbol-13-acetate-treated HepG2cells. Naunyn Schmiedebergs Arch. pharmacol. 2011, 384, 185–196. [Google Scholar] [CrossRef] [PubMed]
  68. Bacchi, E.M.; Sertie, J.A. Antiulcer action of Styrax camporum and Caesalpinia ferrea in rats. Planta Med. 1994, 60, 118–120. [Google Scholar] [CrossRef]
  69. Bertanha, C.S.; Braguine, C.G.; Moraes, A.G.; Gimenez, V.M.; Groppo, M.; Silva, M.; Cunhua, W.R.; Januário, A.H.; Pauletti, P.M. Cyclooxygenase inhibitory properties of nor-neolignans from Styrax pohlii. Nat. Prod. Res. 2012, 26, 2323–2329. [Google Scholar] [CrossRef]
  70. Bertanha, C.S.; Soares, E.; Gonçalves, U.O.; Francielli de Oliveira, P.; Magalhães, L.G.; Rodrigues, V.; Tavares, D.C.; Andrade e Silva, M.L.; Cunha, W.R.; Januário, A.H.; et al. In vitro Antischistosomal and Cytotoxic Activities of Norneolignans from Styrax pohlii A. DC. J. Herbs Spices Med. Plants 2014, 20, 394–401. [Google Scholar] [CrossRef]
Figure 1. Research overview of the Styrax genus.
Figure 1. Research overview of the Styrax genus.
Pharmaceuticals 16 01043 g001
Figure 2. Natural compounds with cytotoxic activity.
Figure 2. Natural compounds with cytotoxic activity.
Pharmaceuticals 16 01043 g002
Figure 3. Natural compounds with antibacterial and antifungal activities.
Figure 3. Natural compounds with antibacterial and antifungal activities.
Pharmaceuticals 16 01043 g003
Figure 4. Natural compounds with antiproliferative and differentiation properties.
Figure 4. Natural compounds with antiproliferative and differentiation properties.
Pharmaceuticals 16 01043 g004
Figure 5. Natural compounds with anti-complement activity.
Figure 5. Natural compounds with anti-complement activity.
Pharmaceuticals 16 01043 g005
Figure 6. Natural compounds with antioxidant activity.
Figure 6. Natural compounds with antioxidant activity.
Pharmaceuticals 16 01043 g006
Figure 7. Natural compounds exhibiting estrogen-promoting activity.
Figure 7. Natural compounds exhibiting estrogen-promoting activity.
Pharmaceuticals 16 01043 g007
Figure 8. Natural compounds as potential acetylcholinesterase inhibitors.
Figure 8. Natural compounds as potential acetylcholinesterase inhibitors.
Pharmaceuticals 16 01043 g008
Figure 9. Natural compounds with matrix metalloproteinase’s activity.
Figure 9. Natural compounds with matrix metalloproteinase’s activity.
Pharmaceuticals 16 01043 g009
Figure 10. Natural compounds with antiasthmatic, antiulcer, and anti-inflammatory activities.The EtOAc fraction of S. camporum displayed antiulcer activity. It reduced the ulcer area and gastric secretion volume and increased the number of collagen fibers [37,68].
Figure 10. Natural compounds with antiasthmatic, antiulcer, and anti-inflammatory activities.The EtOAc fraction of S. camporum displayed antiulcer activity. It reduced the ulcer area and gastric secretion volume and increased the number of collagen fibers [37,68].
Pharmaceuticals 16 01043 g010
Figure 11. Natural compounds with other properties.
Figure 11. Natural compounds with other properties.
Pharmaceuticals 16 01043 g011
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Xia, D.-D.; Han, X.-Y.; Zhang, Y.; Zhang, N. Chemical Constituents and Their Biological Activities from Genus Styrax. Pharmaceuticals 2023, 16, 1043. https://doi.org/10.3390/ph16071043

AMA Style

Xia D-D, Han X-Y, Zhang Y, Zhang N. Chemical Constituents and Their Biological Activities from Genus Styrax. Pharmaceuticals. 2023; 16(7):1043. https://doi.org/10.3390/ph16071043

Chicago/Turabian Style

Xia, Ding-Ding, Xin-Yu Han, Yu Zhang, and Na Zhang. 2023. "Chemical Constituents and Their Biological Activities from Genus Styrax" Pharmaceuticals 16, no. 7: 1043. https://doi.org/10.3390/ph16071043

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop